Samuel Alworth
Co-founder and Chief Executive Officer at AcuraStem
· Los Angeles, CA
Check size
Undisclosed
Lead stage
Clinical Development
Deals tracked
3
Sectors
Biotechnology, Neuroscience
Biotechnology
Neuroscience
Drug Development
Neurodegenerative Diseases
Clinical Development
Pre-IND
Translational Research
Los Angeles, CA
Pasadena, CA
USA
About Samuel
Samuel Alworth is an Executive Officer and Director with experience in institutional investment and corporate governance. Limited public information is available regarding his specific firm affiliation, investment stage focus, or sector specialization
Investment thesis
Pioneering patient-based therapeutics for neurodegenerative diseases like ALS and FTD
AcuraStem is a purpose-driven company on a mission to get promising treatments into patients' hands as quickly as possible, led by data and science while working relentlessly to match the intensity of devastating neurodegenerative disorders.
Recent activity
Live platform data · proprietary, citable layer
Notable portfolio
$7.5M CIRM grant for ALS/FTD Program AS-241
Collaboration with Takeda on ALS/FTD disease modeling
Frequently asked
Does Samuel Alworth invest at Clinical Development stage?
Yes. They invest at Clinical Development, Pre-IND, Translational Research stage.
Their geographic focus includes Los Angeles, CA, Pasadena, CA, USA.
What is their typical check size?
Check size is not publicly disclosed. They currently invest through AcuraStem.
What sectors does Samuel Alworth focus on?
Samuel Alworth primarily invests in Biotechnology, Neuroscience, Drug Development, Neurodegenerative Diseases.
Similar Biotechnology investors
Avijeet Alagathi, CFA
DeepTech · $500K - $3M
CC
Craig Coletta
AI · null
FT
Fernando Torres Navarrete
Biotechnology · Undisclosed
FK
Frank Kung
Healthcare · Undisclosed
Sign up for free to unlock similar investors
Are you a fit for Samuel Alworth?
See your match score free · under a minute